source
- Xenon pauses enrollment in phase 3 depression trials after reports of psychosis and other neuropsychiatric eventsXenon Pharmaceuticals announced it has voluntarily stopped enrolling new patients in its two phase 3 studies of azetukalner for major depressive disorder and bipolar depression. The decision follo…
- BMS abandons $100 million Orum degrader-antibody conjugate after early phase-1 resultsBristol Myers Squibb has decided to stop development of the degrader‑antibody conjugate it purchased from Orum Therapeutics for $100 million after reviewing data from a phase‑1 trial. The experime…